Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Kimberly Maersk-Moller, the Chief Commercial Officer of MiMedx Group, Inc. (NASDAQ:MDXG), a $1.18 billion market cap healthcare company with strong financial health according to InvestingPro metrics, recently executed a series of stock transactions, according to a recent SEC filing. On February 28, Maersk-Moller sold 2,111 shares of MiMedx common stock at an average price of $8.405 per share, resulting in a total sale value of approximately $17,742.
In a subsequent transaction on March 3, she acquired 45,929 shares of restricted stock at no cost. These shares are part of a grant that will fully vest on the third anniversary of the grant, contingent on her continued employment with the company. Additionally, Maersk-Moller received 36,486 stock options on the same day, which will vest in increments of 25% annually, beginning on the first anniversary of the grant date.
Following these transactions, Maersk-Moller holds a total of 314,942 shares of MiMedx common stock.
In other recent news, MiMedx Group Inc . reported its financial results for the fourth quarter of 2024, surpassing market expectations. The company achieved earnings per share (EPS) of $0.07, exceeding the forecast of $0.06, and reported revenue of $93 million, surpassing the anticipated $89.4 million. This marks a 7% increase in revenue compared to the previous year. MiMedx ended the year with $104 million in cash, reflecting a $16 million increase in the fourth quarter. Analyst firms have not provided any new upgrades or downgrades following these results. The company anticipates high single-digit sales growth in 2025, with expectations of maintaining an adjusted EBITDA margin above 20%. MiMedx is also preparing for changes in Medicare Local Coverage Determination (LCD), which are expected to impact pricing and volumes. CEO Joe Capper expressed confidence in the company’s ability to adapt and excel in the evolving market landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.